Home＜ News & Events

News & Events

News Events Media Attention Partner News

 

2020.11
22

TOT BIOPHARM Unveils Results of Phase III Clinical Trial of TAB008（Bevacizumab Injection）in ESMO ASIA for the First Time

(Hong Kong, 22 November 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) announced that the Company has published the phase III clinical research results of its self-developed bevacizumab biosimila…
2020.10
15

TOT BIOPHARM International Company Limited Optimises Company Management Structure to Promote Strategic Development Upgrade

TOT BIOPHARM International Company Limited Optimises Company Management Structureto Promote Strategic Development Upgrade* * *Names Ms. Yeh-Huang, Chun-Yingas Vice Chairman of the BoardAppoints Dr. Liu, Jun as Chief Executive Officer…
2020.08
14

TOT BIOPHARM Announces 2020 Interim Results

TOT BIOPHARM Announces 2020 Interim Results* * *Accelerates Development for UpgradeFocuses on the ADC Platform and Improves Competitiveness (Hong Kong, 13 August 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock c…
2020.07
23

TOT BIOPHARM Announces First Patient Dosed in Phase III Clinical Trial of ADC Candidate TAA013

(Hong Kong, 23 July 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that TOT BIOPHARM’s self-developed HER2 targeted antibody drug conjugate (“ADC”) candidate, TAA013, ha…
2020.04
21

TOT BIOPHARM Self-Developed Biological Drug TAB008 (Pusintin®) Meets Primary Endpoint in Phase III Clinical Trial

(Hong Kong, 21April 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK) is pleased to announce that the randomized Phase III clinical trial of TAB008 (Pusintin®) has recently reached the prede…
2020.04
21

TOT BIOPHARM International Company Limited TOT BIOPHARM Appoints Dr. Liu Jun as Chief Operating Officer

* * * Prepares for Entering Commercial Development Stage Facilitates International Strategic Development Layout (Hong Kong, 21April 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company;” stock code: 1875.HK) is…
2020.03
19

TOT BIOPHARM International Company Limited TOT BIOPHARM Announces 2019 Annual Results

(Hong Kong, 17 March 2020) TOT BIOPHARM International Company Limited (“TOT BIOPHARM” or the “Company”; stock code: 1875.HK), a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative oncology drugs and